CPRC
BMY icon

Consolidated Portfolio Review Corp’s Bristol-Myers Squibb BMY Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,454
Closed -$2.06M – 84
2025
Q3 		$2.06M Sell
45,454
-225
-0.5% -$10.5K 0.26% 96
2025
Q2 		$2.11M Buy
45,679
+164
+0.4% +$8.05K 0.29% 85
2025
Q1 		$2.78M Buy
45,515
+3,449
+8% +$201K 0.44% 59
2024
Q4 		$2.38M Buy
+42,066
New +$2.35M 0.38% 71
2023
Q2 		– Sell
-3,053
Closed -$212K – 318
2023
Q1 		$212K Buy
+3,053
New +$215K 0.06% 259

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Consolidated Portfolio Review Corp's BMY Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 45,454 shares — an estimated $2.06M sold.

Consolidated Portfolio Review Corp first reported a position in BMY in Q1 2023 and held it in 5 quarters. The position peaked at $2.78M in Q1 2025. 2,448 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 45,454 Bristol-Myers Squibb shares in Q4 2025, an estimated $2.06M.
  • Consolidated Portfolio Review Corp first reported a position in Bristol-Myers Squibb in Q1 2023 and held it in 5 quarters.
  • Consolidated Portfolio Review Corp's Bristol-Myers Squibb position peaked at $2.78M in Q1 2025.
  • 2,448 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.